Alexza Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXA)   Watch this stock  
Find more results for ALXA
3.48
-0.02 (-0.64%)
Real-time:   11:14AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.47 - 3.53
52 week 3.40 - 5.93
Open 3.53
Vol / Avg. 14,314.00/168,883.00
Mkt cap 60.41M
P/E     -
Div/yield     -
EPS -1.72
Shares 17.37M
Beta 1.22
Inst. own 48%
Nov 4, 2014
Q3 2014 Alexza Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 9, 2014
Alexza Pharmaceuticals Inc at Morgan Stanley Healthcare Conference - 9:10AM EDT - Add to calendar
Aug 11, 2014
Alexza Pharmaceuticals Inc at Avondale Partners Healthcare 1-1 Conference
Aug 7, 2014
Q2 2014 Alexza Pharmaceuticals Inc Earnings Call - Webcast
Aug 7, 2014
Q2 2014 Alexza Pharmaceuticals, Inc. Earnings Release
Jun 10, 2014
Alexza Pharmaceuticals, Inc. Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -495.61% -82.81%
Operating margin -406.42% 3.70%
EBITD margin - 10.65%
Return on average assets -65.02% -90.42%
Return on average equity - -
Employees 90 -
CDP Score - -

Address

2091 Stierlin Court
MOUNTAIN VIEW, CA 94043
United States - Map
+1-650-9447000 (Phone)
+1-650-9447999 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alexza Pharmaceuticals, Inc. (Alexza) is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system (CNS) conditions. Alexza�s product candidates are based on its technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for systemic drug delivery. As of December 31, 2011, the Company had screened more than 400 drug compounds, identifying approximately 200 drug compounds that demonstrate initial vaporization. The Company's product candidate is ADASUVE (Staccato loxapine). Its other product candidates in active development are AZ-007 (Staccato zaleplon) and Staccato nicotine. In January 2014, Alexza Pharmaceuticals Inc announced that ADASUVE is available in Spain through Grupo Ferrer Internacional S.A.

Officers and directors

Thomas B. King President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark K. Oki Senior Vice President, Finance, Chief Financial Officer, Secretary, Principal Financial Officer and Principal Accounting Officer
Age: 45
Bio & Compensation  - Reuters
Robert A. Lippe Chief Operating Officer, Executive Vice President - Operations
Age: 49
Bio & Compensation  - Reuters
James V. Cassella Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Edwin S. Kamemoto Ph.D. Senior Vice President - Regulatory Affairs
Age: 61
Bio & Compensation  - Reuters
Michael J. Simms Senior Vice President - Operations and Manufacturing
Age: 51
Bio & Compensation  - Reuters
Isaac Stein Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
J. Kevin Buchi Independent Director
Age: 58
Bio & Compensation  - Reuters
Deepika R. Pakianathan Ph.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
J. Leighton Read M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters